GlassScriptPhysician profile
Charissa Duffy
NPI 1689160442
$31,177.41
in general payments reported to CMS, 2019-2025
14 companies · $27K in 2025
The $27K reported for 2025 was more than what 99% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $442 · 2022: $1,184 · 2023: $1,571 · 2024: $751 · 2025: $27K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $21K · Travel and Lodging: $4,558 · Food and Beverage: $4,040 · Education: $8.44.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $20,944.00 |
| Travel and Lodging | $4,558.26 |
| Food and Beverage | $4,040.42 |
| Education | $8.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $26,789.93 | 2022-2025 | Rexulti, Nuedexta |
| Neurocrine Biosciences, INC. | $1,997.16 | 2021-2025 | Ingrezza |
| Acadia Pharmaceuticals INC | $1,348.77 | 2021-2025 | Nuplazid |
| Abbvie INC. | $194.69 | 2022-2023 | |
| Avanir Pharmaceuticals, INC. | $179.98 | 2021-2022 | |
| Alkermes, INC. | $131.34 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $130.94 | 2021-2024 | Austedo Xr |
| Edwards Lifesciences Corporation | $116.82 | 2025 | Sapien 3 Ultra Resilia |
| Janssen Pharmaceuticals, INC | $83.05 | 2021-2023 | Invega Sustenna |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $79.21 | 2023 | |
| Sun Pharmaceutical Industries INC. | $50.00 | 2021 | |
| Lundbeck LLC | $33.23 | 2023-2024 | Rexulti |
| Eisai INC. | $24.93 | 2022 | |
| Idorsia Pharmaceuticals US INC | $17.36 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charissa Duffy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.